Wan-Ming Da

Publications (75) View all

• Article: Analysis of clinical characteristics and prognostic factors of primary mediastinal T-cell lymphoblastic lymphoma.

  Xin Jin, Hai-Feng Zhao, Yong Yu, Dan-Dan Zhao, Hong-Liang Yang, Xiao-Fang Wang, Zhi-Gang Zhao, Ya-Fei Wang, Xiao-Xiong Wu, Wan-Ming DA, Yi-Zhuo Zhang
  [show abstract] [hide abstract]
  ABSTRACT: Lymphoblastic lymphoma (LBL) comprises 2% to 4% of non-Hodgkin lymphomas cases in adults, of which 85% to 90% of LBL in adults is of T-cell phenotype. This study was aimed to evaluate the clinical characteristics and prognostic factors of patients with mediastinal T-LBL. Based on the retrospective analysis of the clinical data of 35 patients with mediastinal T-LBL during the period from January 1998 to January 2011, the clinical characteristics and prognostic factors of mediastinal T-LBL were summarized. The results showed that the total of 35 patients were identified (male 24 and female 11), with a median age of 19 (5 - 52) years. The majority of patients were in stage III/IV, 16 cases (45.7%) presented bulky mediastinal mass. Intrathoracic effusions (pleural, pericardial) were not uncommon (62.9%). Overall survival rate (OS) and progression-free survival rate (PFS) at 3 years for the entire cohort were 36% and 24%, respectively. OS and PFS at 5 years were 25% and 16.7%, respectively. Anemia at diagnosis were an important, independent predictor of OS (P = 0.048). Bulky mass (P = 0.048), superior vena cava syndrome (P = 0.021), and abnormal PLT count at diagnosis was the independent prognostic factors for PFS (P = 0.021). It is concluded that the patients with primary mediastinal T-LBL are characterized by a low incidence, bad prognosis, and short survival. For patients accompanying with anemia, bulky mass and superior vena cava syndrome, their prognosis is worse.
  Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology 03/2013; 21(2):377-82.
• Article: [Salvaged allogeneic hematopoietic stem cell transplantation for refractory/recurrent acute myeloid leukemia].

  Jing-bo Wang, Tong Wu, Wan-ming DA, Chun-rong Tong, Yuan Sun, Yan-li Zhao, Yu-ming Yin, Xing-yu Cao, Yue Lu, Yan-qun Gao, Jia-rui Zhou, Jian-ping Zhang, Rong-mu Luo, Wei Zou, Dao-pei Lu
  [show abstract] [hide abstract]
  ABSTRACT: To evaluate the efficacy of salvaged allogeneic hematopoietic stem cell transplantation (allo-HSCT) for refractory/recurrent acute myeloid leukemia (AML). A total of 45 patients with refractory/recurrent AML were enrolled from September 2006 to April 2010. The median blasts in bone marrow (BM) were 36% (20% to 92%) before conditioning. The donors were identical siblings (6) or unrelated ones (9) or haploidentical family members (30). Conditioning regiments were individualized according to patients' status, the regimen with high-dose cytarabine plus BuCy/CY was mostly used (20). The patients with impaired organ function received above regimen except using fludarabine instead of cyclophosphamide (16). FLAG followed by reduced-intensified BuCy was employed for the recipients with more than 40% blasts in BM (6) to reduce leukemia burden. TBI/CY or TBI/Fludarabine was used for the recipients with extramedullary infiltration of leukemia or multidrug resistant leukemia. G-CSF, MTX, NVT, Vm26, Acla or Thaltipa was added into conditioning regiments according to leukemia character. All but 2 patients attained durable engraftment. The incidence of grade II to IV aGVHD and cGVHD were 34%, 59.1%, respectively. With median follow-up 30 (0.5 - 57) months, the relapse rate was 29.2%. Twenty-nine of 45 (60.2%) patients remained in complete remission since salvaged HSCT. Three-years disease-free survival and overall survival were 60.2% and 62.6%, respectively. Our results indicated that the combination of salvaged HSCT with prophylactic immunotherapy might be a promising modality for treatment of refractory/recurrent AML, even with high leukemia burden.
  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 06/2012; 33(6):467-70.
• Article: The diversity of KIR gene in Chinese Northern Han population and the impact of donor KIR and patient HLA genotypes on outcome following HLA-identical sibling allogeneic hematopoietic stem cell transplantation for hematological malignancy in Chinese people

  Li Ping Dou, De Hua Zheng, Chang Wang, Jun Hua Liu, Jing Fen Sun, Hai Jie Jin, Chun Ji Gao, Li Yu, Wan Ming Da
  [show abstract] [hide abstract]
  ABSTRACT: Killer cell immunoglobulin-like receptors (KIRs) are members of a group of molecules that specifically recognize HLA class I ligands and are found on subsets of human lymphopoetic cells. The number of KIR loci can vary between individuals, resulting in a heterogeneous array of possible KIR genes. The range of observed profiles has been explained by the occurrence of two haplotype families termed A and B, which can be distinguished on the basis of certain KIR sequences. Immunogenetic analysis of different ethnic populations shows significant differences in terms of the distribution for group A and group B haplotypes. Recently, attention has been focused on the role of killer cell immunoglobulin-like receptor (KIR)-ligand incompatibility in the graft-versus-host direction between donor and recipient in allogeneic hematopoietic stem-cell transplantation (ASCT). The goal of this study was to study the frequency of specific KIR genes in Chinese Northern Han population and evaluate the role of KIR-ligand mismatch in Chinese HLA-identical sibling hematopoietic stem cell transplantation patients with hematological malignancy. Here genomic DNA from 150 Northern Chinese Han individuals was typed for the presence or absence of KIR genes. Seventy-four allogeneic stem cell transplantation donor/recipient pairs were typed for HLA-A, B, C and KIR. Sixteen KIR genes were observed in the population, and framework genes 3DL3, 3DP1, 2DL4, and 3DL2 were present in all individuals. Twenty-two different genotypes were found. Group A haplotypes outnumbered group B haplotypes in frequency by approximately 3:1, with individuals having two group A haplotypes accounting for 51.9% (78/150). We observed that 57 out of 74 (77.3%) donor–recipient pairs could be characterized by lack of recipient HLA ligand for donor KIR. We observed that 36 out of 45 (80%) donor–recipient HLA-identical sibling transplant pairs could be characterized by lack of recipient HLA ligand for donor KIR. Cumulative incidence analysis of aGVHD in patients undergoing HLA-identical sibling hematopoietic stem cell transplantation in this study demonstrated a decreased incidence of severe aGVHD in patients lacking HLA ligand for donor-inhibitory KIR2DL1 (31.4 vs. 70%, P=0.029). And also in AML (acute myeloid leukemia) patients lacking HLA ligand for donor-inhibitory KIR and KIR2DL1 (17.6 vs. 75%, P=0.03). Our data demonstrated that the Chinese Han population is distinct in KIR gene frequencies and putative KIR haplotypes in comparison to some other populations. Almost all allogeneic donors could be characterized as having an inhibitory KIR for each of the three known class I ligands. KIR and KIR2DL1 mismatch is associated with lower aGVHD in Chinese after HLA-identical sibling hematopoietic stem cell transplantation.
  International Journal of Hematology 04/2012; 87(4):422-433. · 1.27 Impact Factor
• Article: [Experimental study of SHP-1 promoter methylation in myelodysplastic syndromes and its related mechanism].

  Yi-Zhuo Zhang, Dan-Dan Zhao, Wei-Peng Zhao, Hai-Feng Zhao, Zhi-Gang Zhao, Ya-Fei Wang, Xiao-Xiong Wu, Xiao-Ping Han, Wan-Ming Da
  [show abstract] [hide abstract]
  ABSTRACT: To explore the role of SHP-1 promoter methylation on the pathogenesis and progression in myelodysplastic syndromes (MDS) and its related mechanism. 63 MDS patients were divided into low-grade (LG) group and high-grade (HG) group according to IPSS score system. Bone marrow samples were collected. Methylation specific-PCR (MSP) were used to detect the status of SHP-1 promoter methylation in bone marrow (BM) samples from different risk MDS patients and MDS cell line, SKK-1. Western blot was used to detect signal transduction and activator of transcription (STAT3) activation in SKK-1 cell line and MDS patients. No SHP-1 promoter methylation could be detected in healthy controls BM. Partially methylation was found in SKK-1 cell line. Methylation rate of SHP-1 gene promoter was found in BM of 24.2% of low-grade MDS patients and 63.3% of high-grade MDS patients, the difference between these two groups was statistically significant (P < 0.05); Patients were divided into different groups according to WHO subtype, chromosomal karyotype and blast cells in bone marrow, methylation rates of SHP-1 were significantly higher in RAEB-II, poor karotype group and samples with 0.11-0.19 blast cells (P < 0.05); The phosphorylation protein of STAT3 was detected in SKK-1 cell line. The expression of phosphorylation STAT3 was significantly higher in HG group than in LG group (66.7% vs 18.2%) (P < 0.05). There was a significant correlation between SHP-1 promoter methylation and STAT3 phosphorylation. Abnormal methylation of SHP-1 gene promoter might have tentative role in the pathogenesis and progression of MDS, which may be involved in STAT3 activation. Detection of SHP-1 promoter methylation may be helpful to evaluate the prognosis of MDS.
  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 02/2012; 33(2):108-12.
• Article: [Expression of stromal cell derived factor-1/CXCR4 biology axis in myelosysplastic syndromes].

  Yi-zhuo Zhang, Wan-ming Da, Dan-dan Zhao, Hai-feng Zhao, Xiao-xiong Wu, Hui Wang
  [show abstract] [hide abstract]
  ABSTRACT: To explore the expression of stromal cell derived factor-1 (SDF-1) and its receptor CXCR4 in myelodysplastic syndromes (MDS). A total of 59 patients with a diagnosis of MDS were divided into low-grade (n = 33) and high-grade (n = 26) groups according to international prognostic scoring system (IPSS). Bone marrow (BM) samples were collected. The SDF-1 and VEGF levels in BM plasma, CXCR4 expression on BM CD34(+) cell and the apoptosis of CD34(+) cells were measured. The SDF-1 levels in MDS patients were significantly higher than those of normal controls [(689 ± 190) ng/L, P < 0.05]. And the low-grade group was significantly higher than that of high-grade group [(2301 ± 413) vs (1173 ± 501) ng/L]. CXCR4 expression on CD34(+) cells were significantly higher in high-grade group (68.1% ± 18.8%) than that of both low-grade (21.0% ± 9.7%) and control groups (19.4% ± 5.3%) (P < 0.05). Apoptotic rate of CD34(+) cells were 54.8% ± 10.2% in low-grade group, 24.3% ± 7.9% in high-grade group and 18.5% ± 8.7% in control group. It significantly increased in low-grade group versus other groups (P < 0.05). VEGF levels were significantly higher in MDS patients in low-grade group [(286 ± 97) ng/L] and high-grade group [(407 ± 168) ng/L] versus control group [(157 ± 46) ng/L, P < 0.05]. A positive correlation was found between apoptosis of CD34(+) cells and SDF-1 levels in low-grade group (r = 0.805, P < 0.05), VEGF levels and CXCR4 expression rate in high-grade group (r = 0.683, P < 0.05). The expression of SDF-1/CXCR4 is significantly abnormal in MDS patients. And it is correlated with apoptosis and angiogenesis. Intervention of SDF-1/CXCR4 axis may provide a new therapeutic target.
  Zhonghua yi xue za zhi 12/2011; 91(46):3275-7.